Veeva Systems Inc. · NYSE:VEEV
Veeva Systems — Investor Day (November 2026)
61 slides from Veeva Systems's investor day presentation, Nov 5, 2026
Slide 1: Investor Day
Investor Day November 5, 2026
Slide 2: 2026 Veeva Investor Day Agenda
2026 Veeva Veeva Vision and Strategy Peter Gassner, Founder and CEO Investor Day Customer Perspective: Veeva Basics Nitsa Zuppas, President and Chief of Staff Brian Radecki, Founder and CEO, Rapa Therapeutics Financial Update Brian Van Wagener, CFO Break Customer Perspective: Veeva Falcon Paul Shawa
Slide 3: Safe Harbor and Other Information
Safe Harbor and Other Information This presentation and associated commentary contain forward-looking statements regarding Veeva’s future plans and expected performance, market size and opportunity, and financial outlook, including guidance provided as of August 26, 2026, about Veeva’s expected futu
Slide 4: Peter Gassner
Peter Gassner Founder and CEO
Slide 5: Vision and Values
Vision Building the Industry Cloud for Life Sciences Values Do the Right Thing Customer Success Employee Success Speed A Public Benefit Corporation
Slide 6: Highlights
Highlights • Golden Age of Life Sciences • Strong Execution and Innovation • Industry AI is a Big Opportunity • On Track for $6B in 2030
Slide 7: Strategic Partner to a Critical and Growing Industry
Strategic Partner to a Critical and $2T+ Biopharma & MedTech Growing Industry Growing at 6%+ Source: Evaluate
Slide 8: Growing Market Opportunity $30B+
Growing Market Opportunity Industry Cloud with Industry AI $30B+ Life Sciences TAM Source: Veeva estimates
Slide 9: Agentic Biopharma
Agentic Biopharma The Golden Age of Life Sciences AI Enabling AI Empowering Better Medicines Drug Discovery Patients and Doctors to More Patients
Slide 10: The Industry Cloud for Life Sciences
The Industry Cloud for Life Sciences Applications • Agents • Data • Business Consulting Veeva Falcon Agentic Labor Veeva Veeva Veeva Veeva Development Quality Commercial Data Cloud Cloud Cloud Cloud Business Consulting
Slide 11: Our Long-Term Strategy
Our Long-Term Strategy Complete Connect Deliver AI the Industry Cloud the Industry for the Industry
Slide 12: The Technology Foundation for Product Development
The Technology Foundation for Product Development Clinical Clinical Drug Regulatory Operations Data Safety eTMF EDC Registrations Safety CTMS eCOA Submissions SafetyDocs Payments RTSM Publishing Workbench Study Startup DQS Archive Signal Site Connect Labeling* Study Training Disclosures OpenData Cli
Slide 13: Veeva Clinical Network
Veeva Clinical Network Connecting Sites and Sponsors Sites Sponsors SiteVault Clinical Operations EHR Clinical Data Enabling eSource for the Industry Eliminate Paper | Reduce Cost | Increase Speed
Slide 14: Veeva Study Suite
Veeva Study Suite Making it Easier for Sponsors and CROs to Execute Trials Clinical Operations • Significant CRO Channel Opportunity eTMF | CTMS | Study Startup Site Connect | Study Training Clinical Data • All the Technology Needed to Run a Study EDC | eCOA | RTSM by the study Study Suite planned a
Slide 15: The Technology Foundation for Quality
The Technology Foundation for Quality Quality Assurance Quality Control EHS QualityDocs LIMS Environmental, QMS Environmental Monitoring * Health, and Safety Training Learn GxP Validation Management Batch Release Vault Platform *Planned for future availability
Slide 16: Significant Opportunity in Quality
Significant Opportunity in Quality • 600+ customers • $600M+ revenue run rate • Modernizing LIMS for companies of all sizes • Quality Network to connect CDMOs and biopharma
Slide 17: Veeva Quality Network
Veeva Quality Network Connecting Contract Manufacturers to Biopharma Contract Manufacturers Biopharma QMS QMS QC LIMS QC LIMS
Slide 18: The Technology Foundation for Agentic Commercial
The Technology Foundation for Agentic Commercial Crossix Ostro CRM Suite Content Medical Consumer Patient Agentic CRM PromoMats Medical CRM HCP HCP Campaign Manager Vault Medical Measurement Commercial Events Link Audiences Medical* Align Network MDM Patient CRM Vault Platform *Planned for future av
Slide 19: CRM Leadership
CRM Leadership 200+ 5 top 20 14 top 20 Vault CRM Biopharmas Biopharmas Customers Live Live Committed
Slide 20: The Data Foundation for AI
The Data Foundation for AI OpenData Link Compass Global Reference Data Global Deep Data U.S. Performance Data HCP Key People Patient HCO Key Accounts Prescriber Affiliations National Common Data Architecture
Slide 21: Unique and High-Value Services
Unique and High-Value Services Business Consulting AI-Enabled Services • Strategic and growing • Faster, higher quality implementations • Even more important with AI • Fixed price
Slide 22: Industry AI for Life Sciences
Industry AI for Life Sciences
Slide 23: MAAP Architecture
MAAP Architecture The New Enterprise Technology Landscape Agents Applications Models
Slide 24: Veeva AI Architecture
Veeva AI Architecture Strong Link Falcon Vault Agents Applications Models
Slide 25: Industry AI for Life Sciences
Industry AI for Life Sciences AI in Vault Applications Agentic Labor Helping you do the work Doing the work for you
Slide 26: AI in Vault Applications
AI in Vault Applications Helping you do the work
Slide 27: Helping you do the work
Helping you do the work Direct, secure access to Vault data and content Standard, custom, & user agents Simple, predictable 10% pricing Available today Getting better fast
Slide 28: Agentic Labor: Doing the work for you
Agentic Labor Doing the work for you
Slide 29: Falcon Agents
Falcon Agents • Strong link with Vault applications Strong • Licensed by the agent Falcon Link Vault Agents Applications • Learning a new motion • Product excellence is the goal Models • Potential for rapid adoption
Slide 30: Falcon Agents
Falcon Agents Clinical Regulatory Safety Commercial Intake Interactions Intake MLR TMF Writer Case Management Study Management Submissions Router Monitoring Data Management Developing | Considering
Slide 31: Simplify, Standardize, and Connect
Simplify, Standardize, and Connect Customer Success | Product Excellence
Slide 32: Customer Perspective: Brian Radecki
Customer Perspective: Veeva Basics Brian Radecki Founder and CEO, Rapa Therapeutics
Slide 33: Our Long-Term Strategy
Our Long-Term Strategy Complete Connect Deliver AI the Industry Cloud the Industry for the Industry
Slide 34: Next Generation Enterprise CRM Platform
Next Generation Enterprise CRM Platform
Slide 35: Next Generation Enterprise CRM Platform
Next Generation Enterprise CRM Platform • Better platform and better CRM application • Faster, cheaper, more friendly • Built for AI • Focused on early adopters • Chance for greatness
Slide 36: Capital Allocation
Capital Allocation Product Excellence and Long-Term Growth Disciplined Approach to Acquisitions Share Repurchase Program
Slide 37: Highlights
Highlights • Golden Age of Life Sciences • Strong Execution and Innovation • Industry AI is a Big Opportunity • On Track for $6B in 2030
Slide 38: Brian Van Wagener
Brian Van Wagener Chief Financial Officer
Slide 39: Expect to Meet or Exceed Q3'27 Guidance
Expect to Meet or Exceed Q3’27 Guidance Guidance Total Revenue $932-935 million Subscription Revenue ~$782 million Services Revenue $150-153 million Non-GAAP Operating Income $417-420 million Non-GAAP Fully Diluted $2.33-2.34 Net Income per Share Guidance issued on August 26, 2026. Our Q3’27 guidanc
Slide 40: Financial Update
Financial Long Runway for Growth Update On Track for 2030 Goal Strong Profitability
Slide 41: Strategic Partner to Life Sciences
Strategic Partner to Life Sciences Biopharma Other 92% MedTech Industries 5% 3% Top 20 Enterprise SMB ~50% ~20% ~30% Approximates Q2’27 revenue mix Enterprise includes top 6 CROs, with the remainder of CRO revenues included in SMB
Slide 42: Large and Growing Opportunity $30B+
Large and Growing Opportunity Commercial Solutions 35% Quality Cloud 20% $30B+ Life Sciences TAM Development Cloud 45% FY27E Revenue ~12% Penetrated Source: Evaluate and Veeva estimates Life Sciences TAM: Industry specific applications, agents, data, and consulting Penetration and FY27E revenue base
Slide 43: Strong Growth Across All Areas
Strong Growth Across All Areas $6B 40% $3.71B $3.20B $2.75B 44% 20% $2.36B 45% 47% Commercial Solutions 50% 18% 18% 18% 40% Quality Cloud 18% 37% 38% Development Cloud 32% 35% FY24 FY25 FY26 Today 2030 Goal Today reflects annualized Q2’27 results The 2030 goal is a calendar year-end revenue run rate
Slide 44: Deep and Expanding Product Portfolio
Deep and Expanding Product Portfolio Applications, Agents, and Data for the Industry’s Most Critical Functions 15 Suites 60Products
Slide 45: Long Runway for Growth in Biopharma
Long Runway for Growth in Biopharma Still Early in Most of Our Largest Market Opportunities 100% 100% 50% 50% Current Penetration Subscription Revenue 0% 0% eTMF Core CRM Submissions PromoMats QualityDocs CTMS QMS Crossix Link EDC Safety Compass RTSM eCOA LIMS Other early products Leaders Reference
Slide 46: Significant Opportunity in Industry AI
Significant Opportunity in Industry AI Structural Vault AI Falcon Advantage New value for customers A big new market in Deep industry applications, and revenue for Veeva agentic labor agents, and data
Slide 47: Growing and Profitable Services Portfolio
Growing and Profitable Services Portfolio Business Professional Consulting Services ~20% of services revenue ~80% of services revenue Based on Q2’27 results
Slide 48: Consistent Execution with a Long-Term View
Consistent Execution with a Long-Term View Revenue Run Rate Goal Status 2020 Goal set in 2015 $1B Achieved 2025 Goal set in 2019 $3B Achieved 2030 Goal set in 2024 $6B On Track
Slide 49: Executing Well Against Our Long-term Goal
Executing Well Against Our Long-term Goal On Track for $6B 2030 Revenue Goal $6B Services Revenue $800M Long runway for organic growth Subscription Revenue in existing products $3.7B $645M Services growth driven by Business $5,200M Consulting $3,067M Continued focus on both growth and profitability
Slide 50: Consistently Delivering Growth and Profitability
Consistently Delivering Growth and Profitability $3.69B Revenue $3.20B Non-GAAP Operating Income1 $2.75B $2.36B $2.16B $1.85B $1.64B $1.43B ~44% $1.15B 45% $830M $843M 42% $759M 39% 36% 41% FY22 FY23 FY242 FY25 FY26 FY27E3 Fiscal Year Ending January 31 ¹ A reconciliation of GAAP to non-GAAP measures
Slide 51: Primary Margin Drivers
Primary Margin Drivers Spend Driven by Long-Term Focus on Product Excellence and Customer Success Product Product Lean Teams Development Adoption and Execution
Slide 52: Investing for Product Excellence
Investing for Product Excellence 9% Q2’27 24% Main investment Non-GAAP Very efficient Subscription is product Expense sales and marketing 67% Product Sales and Marketing Supporting Functions Total Non-GAAP Subscription Expense = Product expense + Sales & Marketing expense + Supporting Functions expe
Slide 53: Financial Update
Financial Long Runway for Growth Update On Track for 2030 Goal Strong Profitability
Slide 54: Customer Perspective: Joanne Byrne, Roche
Customer Perspective: Veeva Falcon Joanne Byrne Global Head of Regulatory Operations, Roche
Slide 55: Q&A
Q&A
Slide 56: Appendix
Appendix
Slide 57: Continued Adoption in R&D and Quality
Continued Adoption in R&D and Quality Avg. Products 2.85 3.02 3.24 3.41 3.52 3.58 Per Customer: 1,250 1,196 1,125 1,078 1,025 585 860 558 526 542 550 480 304 299 295 255 239 197 339 361 281 304 236 183 FY22 FY23 FY24 FY25 FY26 Q2’27 Customers with: 5 or More Products 3-4 Products 2 Products or Fewer
Slide 58: Expanding Our Commercial Leadership
Expanding Our Commercial Leadership Avg. Products 4.04 4.02 4.08 4.08 4.26 4.40 Per Customer: 756 730 738 684 693 653 372 383 372 358 366 335 234 228 209 221 221 219 126 138 150 97 107 118 FY22 FY23 FY24 FY25 FY26 Q2’27 Customers with: 8 or More Products 4-7 Products 3 Products or Fewer Fiscal Year
Slide 59: Statement Regarding Use of Non-GAAP Financial Measures
Statement Regarding Use of Non-GAAP Financial Measures We provide the following non-GAAP measures, which we define as financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP: Non-GAAP gross margin, non-GAAP operating
Slide 60: Reconciliation of GAAP to Non-GAAP Measures
Reconciliation of GAAP to Non-GAAP Measures in millions FY'22 FY'23 FY'24 FY'25 FY'26 Operating income on a GAAP basis $ 505.5 $ 459.1 $ 429.3 $ 691.4 $ 916.4 Stock-based compensation expense 234.6 351.9 393.7 437.4 472.7 Amortization of purchased intangibles 18.5 19.5 19.5 18.6 14.1 Litigation sett
Slide 61: Reconciliation of GAAP to Non-GAAP Measures
Reconciliation of GAAP to Non-GAAP Measures Q2'27 Cost of subscription services revenues on a GAAP basis $ 105.7 Stock-based compensation expense (2.2) Amortization of purchased intangibles (1.1) Cost of subscription services revenues on a non-GAAP basis $ 102.4 Q2'27 Research and development expens